2023年4月24日

图片/伤风LifeArc邀请为其最新的应用程序从学术机构£4000万(4980万美元)计划基金四个或五个新的转化罕见疾病中心在英国,还有一个单独的协调中心。LifeArc,自筹资金,医学研究非营利慈善机构,专门从事早期翻译——促进科学发现对患者受益,发展下一代的诊断、治疗和治愈。通过计划,协调新转化研究罕见的疾病中心将利用英国罕见疾病的研究基础和帮助提供新的治疗和诊断患有一种罕见的疾病在英国和世界各地。“在全球范围内,有超过3亿人患有罕见疾病,没有批准治疗90%以上的这些条件。英国有很强的罕见的疾病研究基地,我们希望这些资金将会推动社区,增加体积和深度的研究,培养协作的方法,最终找到答案和解决方案患者患有一种罕见的疾病,“说娜克龙比式,技术副主任Ttransfer LifeArc。LifeArc CEO, Melanie Lee说:“生命科学研究充满了特殊的想法。我们的使命是释放他们的潜能,促进发展的下一代的诊断,治疗和治愈。这£40 m投资罕见疾病转化研究是一个关键的一部分,我们的承诺花费£13亿(16亿美元),到2030年,针对未满足的需求,我们可以开启科学领域,加快医学进步和对患者产生最大的影响。疾病越来越明确定义的基础上离散基因和机制,定义小病人群,所以支持罕见疾病研发平台应该突破在医学上也有广泛的影响。“协作应用程序,由英国学术机构,被邀请形成中心,旨在加强英国罕见疾病的转化能力。 This includes increasing the volume of rare disease research delivered and catalyzing translation of the rare disease research base, as well as supporting the establishment and progression of careers in rare disease translational research. It will also increase the understanding of the needs of rare disease patients with industry and policy makers, and become a central point for engagement with the patient community. The investment is part of LifeArc’s broader commitment to the rare disease translational research field. Most recently, the charity awarded a total of £3 million ($3.7 million) to six U.K. universities to accelerate research to help people living with rare diseases. In addition, the LifeArc Philanthropic Fund awards grants to academics with promising rare disease translational research projects and since 2017, £14.6 million ($18.2 million) has been awarded to 45 research projects, addressing 33 rare disease indications. Last year, AbbVie acquired LifeArc portfolio company DJS Antibodies Limited, in a deal worth $255 million.